Neumora Therapeutics Long Term Debt 2023-2025 | NMRA

Prices Financials Revenue & Profit Assets & Liabilities Margins Price Ratios Other Ratios Other Metrics

Total Assets Cash on Hand Long Term Debt Total Liabilities

Neumora Therapeutics long term debt from 2023 to 2025. Long term debt can be defined as the sum of all long term debt fields.

Prices Financials Revenue & Profit Assets & Liabilities Margins Price Ratios Other Ratios Other Metrics

Total Assets Cash on Hand Long Term Debt Total Liabilities

Neumora Therapeutics long term debt from 2023 to 2025. Long term debt can be defined as the sum of all long term debt fields.

Related Stocks
Company Name	Market Cap
AstraZeneca (AZN)	$222.5B
Amgen (AMGN)	$159.7B
Gilead Sciences (GILD)	$139.4B
Vertex Pharmaceuticals (VRTX)	$121.3B
Bristol Myers Squibb (BMY)	$96.3B
GSK (GSK)	$78.4B
CSL (CSLLY)	$77.4B
Regeneron Pharmaceuticals (REGN)	$61.6B
Alnylam Pharmaceuticals (ALNY)	$41.2B
Argenex SE (ARGX)	$34.4B
BioNTech SE (BNTX)	$26.7B
Royalty Pharma (RPRX)	$20.4B
Biogen (BIIB)	$19.5B
Insmed (INSM)	$19.3B
Illumina (ILMN)	$15.6B
Genmab (GNMSF)	$14.2B
Genmab (GMAB)	$13.8B
Incyte (INCY)	$13.5B
Moderna (MRNA)	$12.7B
Exelixis (EXEL)	$12.4B
BioMarin Pharmaceutical (BMRN)	$11.2B
QIAGEN (QGEN)	$10.7B
Ascendis Pharma (ASND)	$10.7B
Swedish Orphan Biovitrum (BIOVF)	$10.4B
Exact Sciences (EXAS)	$10.2B
Verona Pharma American Depositary Share (VRNA)	$8.9B
Blueprint Medicines (BPMC)	$8.4B
Bio-Techne Corp (TECH)	$8.2B
Roivant Sciences (ROIV)	$7.9B
Regencell Bioscience Holdings (RGC)	$7.3B